10X GENOMICS Valuation
| 1KJ Stock | EUR 12.61 0.07 0.56% |
At this time, the entity appears to be overvalued. 10X GENOMICS DL shows a prevailing Real Value of €12.07 per share. The current price of the entity is €12.61. Our model approximates the value of 10X GENOMICS DL from inspecting the entity fundamentals such as revenue of 503.71 M, and Profit Margin of (0.33) % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that 10X GENOMICS's price fluctuation is slightly risky at this time. Calculation of the real value of 10X GENOMICS DL is based on 3 months time horizon. Increasing 10X GENOMICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the 10X stock is determined by what a typical buyer is willing to pay for full or partial control of 10X GENOMICS DL. Since 10X GENOMICS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 10X Stock. However, 10X GENOMICS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.61 | Real 12.07 | Hype 12.61 |
The real value of 10X Stock, also known as its intrinsic value, is the underlying worth of 10X GENOMICS DL Company, which is reflected in its stock price. It is based on 10X GENOMICS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of 10X GENOMICS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of 10X GENOMICS DL helps investors to forecast how 10X stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 10X GENOMICS more accurately as focusing exclusively on 10X GENOMICS's fundamentals will not take into account other important factors: 10X GENOMICS Total Value Analysis
10X GENOMICS DL is presently estimated to have takeover price of 0 with market capitalization of 5.23 B, debt of 70.82 M, and cash on hands of 621.96 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the 10X GENOMICS fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 5.23 B | 70.82 M | 621.96 M |
10X GENOMICS Investor Information
About 100.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 0.76. 10X GENOMICS DL had not issued any dividends in recent years. Based on the key indicators related to 10X GENOMICS's liquidity, profitability, solvency, and operating efficiency, 10X GENOMICS DL is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.10X GENOMICS Asset Utilization
One of the ways to look at asset utilization of 10X is to check how much profit was generated for every dollar of assets it reports. 10X GENOMICS DL shows a negative utilization of assets of -0.0892 percent, losing €8.92E-4 for each euro of assets held by the entity. Inadequate asset utilization signifies that the company is being less competent with each euro of assets it shows. Put another way, asset utilization of 10X GENOMICS DL shows how discouraging it operates for each euro spent on its assets.10X GENOMICS Ownership Allocation
10X GENOMICS holds a total of 95.6 Million outstanding shares. The majority of 10X GENOMICS DL outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 10X GENOMICS DL to benefit from reduced commissions. Hence, institutional investors are subject to a different set of regulations than regular investors in 10X GENOMICS. Please pay attention to any change in the institutional holdings of 10X GENOMICS DL as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million sixty-four thousand eight hundred eighty invesors are currently shorting 10X GENOMICS expressing very little confidence in its future performance.10X GENOMICS Profitability Analysis
The company reported the revenue of 503.71 M. Net Loss for the year was (504.02 M) with profit before overhead, payroll, taxes, and interest of 416.4 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates 10X GENOMICS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in 10X GENOMICS and how it compares across the competition.
About 10X GENOMICS Valuation
The stock valuation mechanism determines 10X GENOMICS's current worth on a weekly basis. Our valuation model uses a comparative analysis of 10X GENOMICS. We calculate exposure to 10X GENOMICS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of 10X GENOMICS's related companies.10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.
8 Steps to conduct 10X GENOMICS's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates 10X GENOMICS's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct 10X GENOMICS's valuation analysis, follow these 8 steps:- Gather financial information: Obtain 10X GENOMICS's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine 10X GENOMICS's revenue streams: Identify 10X GENOMICS's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research 10X GENOMICS's industry and market trends, including the size of the market, growth rate, and competition.
- Establish 10X GENOMICS's growth potential: Evaluate 10X GENOMICS's management, business model, and growth potential.
- Determine 10X GENOMICS's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate 10X GENOMICS's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for 10X Stock analysis
When running 10X GENOMICS's price analysis, check to measure 10X GENOMICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X GENOMICS is operating at the current time. Most of 10X GENOMICS's value examination focuses on studying past and present price action to predict the probability of 10X GENOMICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X GENOMICS's price. Additionally, you may evaluate how the addition of 10X GENOMICS to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |